Amid ongoing challenges in the biotech sector, including clinical trial failures and FDA rejections, CEOs of 15 Korean biotech firms have begun purchasing their own shares to stabilize company stock and signal commitment to corporate value. This spike in share buybacks follows a significant drop in the KRX Health Care Index, which has fallen nearly 40% since February. Notable purchases include Kolon TissueGene and Peptron executives, while experts caution that true recovery hinges on tangible clinical successes rather than just executive actions. Overall, while these buybacks are seen as positive for market sentiment, sustainable recovery will require clear progress in research and development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://en.sedaily.com/finance/2026/08/05/korean-biotech-ceos-buy-shares-to-steady-battered-stocks
